ANI Pharmaceuticals(ANIP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANIP ANI Pharmaceuticals

Market Closed 03-28 16:00:00 EDT

67.61

-0.75

-1.10%

盘后67.61

+0.000.00%

19:17 EDT

High68.49	Low67.02	Vol356.16K
Open68.14	D1 Closing68.36	Amplitude2.15%
Mkt Cap1.47B	Tradable Cap1.13B	Total Shares21.77M
T/O24.08M	T/O Rate2.13%	Tradable Shares16.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ANIP","market":"US","secType":"STK","nameCN":"ANI Pharmaceuticals","latestPrice":67.61,"timestamp":1743192000000,"preClose":68.36,"halted":0,"volume":356164,"hourTrading":{"tag":"盘后","latestPrice":67.61,"preClose":67.61,"latestTime":"19:17 EDT","volume":62073,"amount":4196794.83,"timestamp":1743203822003},"delay":0,"floatShares":16742600,"shares":21773510,"eps":-0.456324,"marketStatus":"Market Closed","change":-0.75,"latestTime":"03-28 16:00:00 EDT","open":68.14,"high":68.49,"low":67.02,"amount":24078160.91896,"amplitude":0.021504,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.456324,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1064980800000,"exchange":"NASDAQ","adjPreClose":68.36,"preHourTrading":{"tag":"盘前","latestPrice":67.7,"preClose":68.36,"latestTime":"08:01 EDT","volume":122,"amount":8260.71943,"timestamp":1743163295939},"postHourTrading":{"tag":"盘后","latestPrice":67.61,"preClose":67.61,"latestTime":"19:17 EDT","volume":62073,"amount":4196794.83,"timestamp":1743203822003},"volumeRatio":0.7790914642319472,"impliedVol":0.5825,"impliedVolPercentile":0.912},"requestUrl":"/m/hq/s/ANIP","defaultTab":"news","newsList":[{"id":"2523685649","title":"FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda","url":"https://stock-news.laohu8.com/highlight/detail?id=2523685649","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523685649?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 23:20","pubTimestamp":1743175200,"startTime":"0","endTime":"0","summary":"Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous  formulation of the blockbuster drug Keytruda .This filing seeks the agency’s nod for the SC version across all solid tumor indications for which the drug’s intravenous  version is already approved.A final decision is expected by Sept. 23, 2025.The regulatory filing is supported by data from the pivotal phase III 3475A-D77 study that evaluated Keytruda SC against the IV version  for the first-line treatment of adult patients with metastatic non-small cell lung cancer. As announced by Merck in November, the study achieved its primary endpoints, showing that the treatment with the SC version of the drug was at least as effective as the IV version.An approval of the SC version also benefits both patients and physicians. Delivering a drug SC instead of IV can significantly reduce administrat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-mercks-filing-subcutaneous-152000184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJT1NW94.SGD","LU1989772923.USD","BK4516","ANIP","LU0965509010.AUD","LU0058720904.USD","LU1066053197.SGD","SG9999001176.SGD","SG9999015341.SGD","LU1066051811.HKD","IE00BN8TJ469.HKD","LU0861579265.USD","BK4585","LU1934455863.HKD","LU1989772840.SGD","SG9999002224.SGD","LU0208291251.USD","LU1983299246.USD","LU1941712264.USD","MRK","SG9999015358.SGD","IE00B4R5TH58.HKD","BK4139","LU2112291526.USD","IE0002141913.USD","IE000M9KFDE8.USD","LU1023059063.AUD","IE00BSNM7G36.USD","IE00BLSP4239.USD","LU1116320737.USD","SG9999014575.USD","LU0320765646.SGD","LU0965509283.SGD","LU1585245621.USD","BK4550","IE00BJJMRZ35.SGD","LU1037948541.HKD","LU0985320562.USD","CTMX","LU0289739699.SGD","LU2023250843.SGD","LU2361044865.SGD","LU0320765489.SGD","LU1093756325.SGD","LU0070302665.USD","ETNB","LU1066051498.USD","LU1037948897.HKD","LU0266013472.USD"],"gpt_icon":0},{"id":"2522070500","title":"5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2522070500","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522070500?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:11","pubTimestamp":1742904660,"startTime":"0","endTime":"0","summary":"Wall Street is suffering from volatility in the first quarter of 2025. Out of the three large-cap indexes, the S&P 500 and the Nasdaq Composite are in negative territory year to date, while the Dow has remained almost flat. The small-cap benchmarks — the Russell 2000 and the S&P 600 — are also in the negative zone year to date. Similarly, the mid-cap-specific S&P 400 index is also in the red.Despite this headwind, a handful of mid-cap stocks with a top Zacks Rank is set for solid returns in the short term. Five such stocks are Brinker International Inc. EAT, Mattel Inc. MAT, Century Aluminum Co. CENX, SkyWest Inc. SKYW and ANI Pharmaceuticals Inc. ANIP.Investment in mid-cap stocks is often recognized as a good portfolio diversification strategy. These stocks combine the attractive attributes of both small and large-cap stocks. Top-ranked, mid-cap stocks have a high potential to enhance their profitability, productivity and market share. These may also become large caps over time.The av","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-top-ranked-mid-cap-121100504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4008","BK4209","EAT","MAT","BK4153","CENX","LU1559883803.SGD","BK4007","LU0566484027.USD","SKYW","ANIP","BK4500","BK4190"],"gpt_icon":0},{"id":"2522079582","title":"FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2522079582","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522079582?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:56","pubTimestamp":1742903760,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis  and slow disability accumulation independent of relapse activity in adults.The filing has been granted priority review by the FDA, bringing down the review period by four months. A final decision is expected by Sept. 28, 2025.The FDA filing is supported by data from three late-stage studies — one  in nrSPMS and two  in relapsing MS . Data from these studies showed that patients treated with tolebrutinib delayed the time to onset of six-month confirmed disability progression when compared to placebo. A similar regulatory filing for the drug is currently under review by the EMA, which is also supported by data from these studies.Per Sanofi, the above results make tolebrutinib the first and the only brain-penetrant BTK inhibitor to treat both the above MS indications. If approved, tolebruti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-sanofis-filing-multiple-115600487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIP","LU2133065610.SGD","SNY","LU2028103732.USD","IE00B66KJ199.SGD","IE00BFXG1179.USD","LU0225283273.USD","BK4504","MG","IE0031619046.USD","LU0106261372.USD","LU1162221912.USD","LU2023251221.USD","BK4516","LU2271345857.HKD","LU0158827948.USD","LU1989772840.SGD","BK4534","IE00B19Z4B17.USD","ETNB","BK4585","LU2111349929.HKD","BK4123","BK4588","LU0098860793.USD","BK4581","LU1732799900.SGD","LU1732800096.USD","LU0106831901.USD","LU0267386448.USD","LU0795875169.SGD","LU0158827781.USD","LU1720051017.SGD","LU2357305700.SGD","LU1548497426.USD","CTMX","LU1363072403.SGD","LU1720051108.HKD","LU2089283258.USD","SNYNF","LU1668664300.SGD","LU1074936037.SGD","IE00BKVL7J92.USD","LU0314104364.USD","LU0912757837.SGD","BK4139","LU0320765646.SGD","LU0971096721.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2522923705","title":"Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think \"Yes\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2522923705","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522923705?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 00:45","pubTimestamp":1742834705,"startTime":"0","endTime":"0","summary":"Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score , which looks beyond the traditional growth attributes to analyze a company's real growth prospects.ANI Pharmaceuticals  is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.Research shows that stocks carrying the best growth features consistently beat the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ani-anip-solid-growth-stock-164505177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ANIP"],"gpt_icon":0},{"id":"2522177492","title":"Wall Street Analysts Think ANI (ANIP) Could Surge 26.83%: Read This Before Placing a Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2522177492","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522177492?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 21:55","pubTimestamp":1742824506,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals  closed the last trading session at $64.26, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $81.50 indicates a 26.8% upside potential.The average comprises eight short-term price targets ranging from a low of $62 to a high of $94, with a standard deviation of $9.13. While the lowest estimate indicates a decline of 3.5% from the current price level, the most optimistic estimate points to a 46.3% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-think-ani-135506757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIP","BK4007"],"gpt_icon":0},{"id":"2522774922","title":"Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522774922","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522774922?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 21:55","pubTimestamp":1742824502,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals, Inc.  reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ANIP's 50-day simple moving average broke out above its 200-day moving average; this is known as a \"golden cross.\". A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a positive trend reversal. The third stage is when a stock continues the upward momentum to higher prices.Over the past four weeks, ANIP has gained 10.9%. The company currently sits a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/buy-ani-pharmaceuticals-anip-golden-135502761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ANIP"],"gpt_icon":0},{"id":"2521940256","title":"Elevation Oncology Plunges 42% on Ending Development of Lead Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2521940256","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521940256?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 01:03","pubTimestamp":1742576580,"startTime":"0","endTime":"0","summary":"Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on its lead pipeline drug EO-3021 for treating advanced, unresectable or metastatic gastric and gastroesophageal junction  cancers.Data from the study showed that patients who were treated with ELEV’s lead drug showed an objective response rate  of 22.2% —out of 36 evaluable patients, there was one complete response and seven partial responses.Following the disappointing study results, Elevation Oncology decided not to pursue further clinical development of EO-3021. Instead, the company will now shift its focus to solid tumor candidate EO-1022, for which an investigational new drug  filing with the FDA is expected next year. As a result of this decision, ELEV is now without a pipeline candidate in clinical development. These factors were likely responsible for the significant drop in share price.In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elevation-oncology-plunges-42-ending-170300990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIP","BK4139","BK4585","BK4007","ORR","BK4539","CTMX","ETNB","ELEV"],"gpt_icon":0},{"id":"2521946256","title":"Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2521946256","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521946256?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 01:01","pubTimestamp":1742576460,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.The company also granted an option to underwriters of the issue to purchase an additional 3.75 million shares at the same price.The secondary offering is expected to close today.Akebia’s shares fell more than 28% yesterday after the announcement. Though the issue does not significantly dilute the existing shareholder base, the issue price per share did not sit well with investors. The issue price was at a discount to the closing price on Thursday, with the stock closing at $2.04.Year to date, shares of Akebia have outperformed the industry.Akebia plans to use the net proceeds from this new issue and its existing cash balance to fund working capital and general corporate purposes, which may include supporting research, development and commercial activities for its marketed and pipeline drugs.A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akebia-stock-drops-28-pricing-170100693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","BK4007","AKBA","BK4139","BK4585","ANIP","ETNB"],"gpt_icon":0},{"id":"2521361282","title":"Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521361282","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521361282?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:40","pubTimestamp":1742564408,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics  been one of those stocks this year?Let's take a closer look at the stock's year-to-date performance to find out.Corcept Therapeutics is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.Based on the latest available data, CORT has gained about 14.3% so far this year. Meanwhile, stocks in the Medical group have gained about 4.9% on average. This means that Corcept Therapeutics is performing better than its sector in terms of year-to-date returns.Another stock in the Medical sector, ANI Pharmaceuticals , has outperformed the sector so far this year. The stock's year-to-date retur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-cort-stock-outpacing-134008027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CORT","BK4532","ANIP","BK4007","LU1559883803.SGD","LU0566484027.USD"],"gpt_icon":0},{"id":"2520160326","title":"SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2520160326","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520160326?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 01:38","pubTimestamp":1742405880,"startTime":"0","endTime":"0","summary":"Per the company, this patient died of acute liver failure. While acute liver injury is a known risk of Elevidys, this is the first time a death has been reported of anyone taking the therapy. However, Sarepta stated that the patient also had a recent CMV infection, which may have contributed to the outcome, as CMV can damage the liver.Sarepta has reported the event to health authorities, clinical study investigators and prescribing physicians. It intends to update Elevidys’ prescribing information accordingly. Despite the incident, the company maintains that the benefit-risk profile of its gene therapy remains positive, with over 800 patients treated in clinical studies or commercial use.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-nosedives-27-patient-death-173800583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RHHBY","CTMX","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","SRPT","ANIP","03165","IE0009355771.USD","IE00B2B36J28.USD","BK4585","IE0002141913.USD","BK4139","IE00BJJMRZ35.SGD","BK4007"],"gpt_icon":0},{"id":"2520133878","title":"Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea","url":"https://stock-news.laohu8.com/highlight/detail?id=2520133878","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520133878?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 21:32","pubTimestamp":1742391137,"startTime":"0","endTime":"0","summary":"Ani Pharmaceuticals  said Wednesday it launched nitazoxanide tablets in 500 mg dosages, which are the generic version of the reference listed drug Alinia, indicated for the treatment of diarrhea.The biopharmaceutical company said annual sales of nitazoxanide tablets in the US totaled $36.1 million in 2024.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","ANIP"],"gpt_icon":0},{"id":"2520172678","title":"ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq","url":"https://stock-news.laohu8.com/highlight/detail?id=2520172678","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520172678?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:19","pubTimestamp":1742300366,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals  said Tuesday that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding on global net revenue of Iluvien and Yutiq for a one-time payment of $17.3 million.The company said it financed the buyout with cash on hand, and that no additional royalty is due to SWK on net revenue beginning Jan. 1 of this year and forward.Shares of the company were down more than 1% in recent Tuesday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANIP","BK4007"],"gpt_icon":0},{"id":"2520281106","title":"BRIEF-ANI Pharmaceuticals Announces Buyout Of Royalty Obligation For Iluvien And Yutiq","url":"https://stock-news.laohu8.com/highlight/detail?id=2520281106","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520281106?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 18:55","pubTimestamp":1742295347,"startTime":"0","endTime":"0","summary":"BRIEF-ANI Pharmaceuticals Announces Buyout Of Royalty Obligation For Iluvien And YutiqMarch 18 (Reuters) - ANI Pharmaceuticals Inc ANIP.O:ANI PHARMACEUTICALS ANNOUNCES BUYOUT OF ROYALTY OBLIGATION FOR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nTUA5XSC9N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANIP"],"gpt_icon":0},{"id":"2520623662","title":"ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®","url":"https://stock-news.laohu8.com/highlight/detail?id=2520623662","media":"GlobeNewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520623662?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 18:50","pubTimestamp":1742295000,"startTime":"0","endTime":"0","summary":"BAUDETTE, Minn., March 18, 2025  -- ANI Pharmaceuticals, Inc.   today announced that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC  on worldwide net revenues of ILUVIEN and YUTIQ for a one-time payment of $17.25 million. Under the terms of the agreement, upon making the buyout payment, no further royalty is due to SWK on net revenues beginning January 1, 2025, forward. ANI funded the buyout with cash on hand.Nikhil Lalwani, President and CEO of ANI stated, “This transaction reflects our commitment to strengthening our Retina portfolio and maximizing the long-term value of ILUVIEN and YUTIQ. By eliminating this royalty obligation, we have enhanced our financial flexibility and ability to accelerate growth as we pursue our purpose of ‘Serving Patients, Improving Lives.’”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ani-pharmaceuticals-announces-buyout-royalty-105000154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","LU0306806265.USD","ANIP","BK4588","LU0225771236.USD","LU0306807586.USD","LU0321505868.SGD","LU0985481810.HKD","BK4161","BK4566","LU0225284248.USD","SWK","BK4597","LU0321505439.SGD"],"gpt_icon":0},{"id":"2520640898","title":"Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2520640898","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520640898?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 17:01","pubTimestamp":1742288480,"startTime":"0","endTime":"0","summary":"The end of the earnings season is always a good time to take a step back and see who shined . Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco .The 17 pharmaceuticals stocks we track reported a mixed Q4. As a group, revenues beat analysts’ consensus estimates by 1.6%.In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results.Originally established as a division of pharmaceutical giant Eli Lilly before becoming independent in 2018, Elanco Animal Health  develops and sells medications, vaccines, and other health products for pets and farm animals across more than 90 countries.Elanco reported revenues of $1.02 billion, down 1.4% year on year. This print exceeded analysts’ expectations by 1.1%. Despite the top-line beat, it was still a slower quarter for the company with a significant miss of analysts’ full-year EPS guidance estimates.The stock is down 4.4% since reporti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-earnings-roundup-elanco-nyse-090120898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VTRS","ELAN","ANIP","ZTS","NYSE"],"gpt_icon":0},{"id":"2520066845","title":"AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2520066845","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520066845?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 00:05","pubTimestamp":1742227500,"startTime":"0","endTime":"0","summary":"Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna  for label expansion in generalized myasthenia gravis  indication.Data from the study showed that treatment with Uplizna ‘demonstrated durable and sustained efficacy’ in AChR-positive  gMG patients over 52 weeks. These findings were assessed using the Myasthenia Gravis Activities of Daily Living  scores, a patient-reported tool that measures the impact of the disease’s symptoms on a person's ability to perform daily activities. Patients treated with Uplizna for a year showed a 2.8-point improvement over placebo. Per Amgen, about 72% of AChR+ patients in the Uplizna group had an improvement of three or more points in the MG-ADL score compared to 45% in the placebo group.There was also a change in the Quantitative Myasthenia Gravis  score, a physician assessment tool for quantifying disease severity. 69% of AChR+ patients treated with Uplizna showed an improvement of three or mo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgn-posts-upbeat-data-uplizna-160500075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2112291526.USD","IE00B2B36J28.USD","BK4566","BK4599","LU0109394709.USD","BK4588","CTMX","LU0889565916.HKD","ARGX","AMGN","LU2242652126.USD","IE0002141913.USD","LU0122379950.USD","BK4139","BK4581","IE00BFTCPJ56.SGD","BK4534","IE0009355771.USD","LU1023059063.AUD","LU1571399168.USD","BK4007","ANIP","BK4533","LU0868494617.USD","LU1983299246.USD","IE00B4R5TH58.HKD","LU0058720904.USD","BK4505","IE00BJJMRZ35.SGD","LU0289739699.SGD","SG9999001440.SGD","BK4585","LU1061106388.HKD","LU2242646821.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2520498075","title":"ANI Pharmaceuticals Price Target Maintained With a $94.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520498075","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520498075?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 19:00","pubTimestamp":1742209200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANIP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2025 07:00 ET (11:00 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIP"],"gpt_icon":0},{"id":"2519333323","title":"BUZZ-U.S. STOCKS ON THE MOVE-Washington Trust, Centessa Pharma, Kingstone","url":"https://stock-news.laohu8.com/highlight/detail?id=2519333323","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519333323?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 01:49","pubTimestamp":1741974582,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Washington Trust, Centessa Pharma, KingstoneEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL4N3PX0YL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRTG","LU0724618789.USD","AU","LU1914381329.SGD","CHTR","PB","SMTC","LU0820562030.AUD","MACW.SI","LU0061474705.USD","XOM","CTRA","KEY","PD","LU1582987324.SGD","WASH","ANIP","CVX","LU2456880835.USD","BK4514","RBRK","LU0456855351.SGD","SOL","ALAB","GOGO","ITGR","NEM","CVS","RDUS","PTCT","IE000ITXATA3.USD","MTB","ABT","LU2065171311.SGD","HBAN","CHKP","KINS","IE00BK4W5M84.HKD","CCI","DOCU","SLB","LU0157215616.USD","WAY","TRUMP.USD.CC","PEP","ULTA"],"gpt_icon":1},{"id":"2519802277","title":"BUZZ-ANI Pharma rises on expanded US approval for eye-disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2519802277","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519802277?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 21:42","pubTimestamp":1741959744,"startTime":"0","endTime":"0","summary":"BUZZ-ANI Pharma rises on expanded US approval for eye-disease drug** Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 2% to $62.70** Co says the U.S. FDA has given expanded approval for Iluvien to treat chronic, non-infectious uveitis affecting the posterior segment of the eye ** NIU-PS is characterized by inflammation of the retina or optic nerve of the eye** Iluvien is already approved by the FDA to treat another eye condition called diabetic macular edema      ** Co plans to market Iluvien under the combined label in the U.S. later this year** Up to last close, ANIP has fallen 7.2% in the past 12 months  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL4N3PX0UQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIP","BK4007"],"gpt_icon":0},{"id":"2519805733","title":"Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Reduced Government Shutdown Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2519805733","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519805733?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 20:26","pubTimestamp":1741955209,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.9% and the actively traded Invesco QQQ Trust (QQQ) advanced 1.3% in Friday's premarket activity, amid a reduced risk of a US","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLE","ANIP","VIS","XLV","IYE","FAZ","FAS","IGM","IPK","VHT.AU","IYJ","BAC","UNG","FDN","XLP",".IXIC","XLK","IBB",".SPX","EXI","RTH","XLI","PMR","QQQ","SLV","SPY.AU","RTH.AU","XSD","XLY","IYK","IYH","MRC.AU","MRC","VHT","XLF","EEM","IGV","VDC","XRT","EQR","SOXX","BITO","USO","RLX","BV","SPY","IYW"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.anipharmaceuticals.com","stockEarnings":[{"period":"1week","weight":0.0521},{"period":"1month","weight":0.229},{"period":"3month","weight":0.2426},{"period":"6month","weight":0.1502},{"period":"1year","weight":-0.022},{"period":"ytd","weight":0.223}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.","yearOnYearQuotes":[{"month":1,"riseRate":0.68,"avgChangeRate":0.064504},{"month":2,"riseRate":0.44,"avgChangeRate":0.015273},{"month":3,"riseRate":0.4,"avgChangeRate":-0.024442},{"month":4,"riseRate":0.541667,"avgChangeRate":0.137911},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.019321},{"month":6,"riseRate":0.64,"avgChangeRate":0.036553},{"month":7,"riseRate":0.44,"avgChangeRate":-0.036667},{"month":8,"riseRate":0.44,"avgChangeRate":-0.010558},{"month":9,"riseRate":0.44,"avgChangeRate":0.023941},{"month":10,"riseRate":0.48,"avgChangeRate":-0.035044},{"month":11,"riseRate":0.6,"avgChangeRate":0.085385},{"month":12,"riseRate":0.44,"avgChangeRate":-0.053148}],"exchange":"NASDAQ","name":"ANI Pharmaceuticals","nameEN":"ANI Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ANI Pharmaceuticals(ANIP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ANI Pharmaceuticals(ANIP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ANI Pharmaceuticals,ANIP,ANI Pharmaceuticals股票,ANI Pharmaceuticals股票老虎,ANI Pharmaceuticals股票老虎国际,ANI Pharmaceuticals行情,ANI Pharmaceuticals股票行情,ANI Pharmaceuticals股价,ANI Pharmaceuticals股市,ANI Pharmaceuticals股票价格,ANI Pharmaceuticals股票交易,ANI Pharmaceuticals股票购买,ANI Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ANI Pharmaceuticals(ANIP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ANI Pharmaceuticals(ANIP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction